in Health

HCQ Study Shows It’s Efficacy.

There is so much proof for early treatment, so why this push for an experimental deadly “Vaccine”

by Colin October 4, 2021, 3:03 pm 1.3k Views

COVID VACCINE INJURIES - ANOTHER LIFE SHATTERED

COVID VACCINE INJURIES – ANOTHER LIFE SHATTERED

Early Treatments with HCQ Work. How and Why Are We Pushing These “Vaccines”

Reviews in Cardiovascular Medicine

2021, Vol. 22

Issue (3): 1063-1072 DOI: 10.31083/j.rcm2203116

Special Issue: Utilizing Technology in the COVID 19 era

Original Research

Previous articles |

Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients

Matthieu MILLION^1,^*(

), Jean-Christophe LAGIER¹, Hervé TISSOT-DUPONT¹, Isabelle RAVAUX¹, Catherine DHIVER¹, Christelle TOMEI¹, Nadim CASSIR¹, Léa DELORME², Sébastien CORTAREDONA², Sophie AMRANE², Camille AUBRY², Karim BENDAMARDJI¹, Cyril BERENGER², Barbara DOUDIER¹, Sophie EDOUARD¹, Marie HOCQUART², Morgane MAILHE¹, Coralie PORCHETO¹, Piseth SENG¹, Catherine TRIQUET¹, Stéphanie GENTILE³, Elisabeth JOUVE³, Audrey GIRAUD-GATINEAU², Herve CHAUDET², Laurence CAMOIN-JAU⁴, Philippe COLSON¹, Philippe GAUTRET², Pierre-Edouard FOURNIER², Baptiste MAILLE⁵, Jean-Claude DEHARO⁵, Paul HABERT⁶, Jean-Yves GAUBERT⁶, Alexis JACQUIER⁶, Stéphane HONORE⁷, Katell GUILLON-LORVELLEC¹, Yolande OBADIA², Philippe PAROLA², Philippe BROUQUI¹, Didier RAOULT¹

¹IHU-Méditerranée Infection, Aix Marseille Univ, Assistance Publique Hôpitaux de Marseille (AP-HM), Institut de recherche pour le développement (IRD), Unité Microbes Evolution Phylogénie et Infections (MEPHI),13005 Marseille, France
²IHU-Méditerranée Infection, Aix Marseille Univ, Assistance Publique Hôpitaux de Marseille (AP-HM), Institut de recherche pour le développement (IRD),
Unité Vecteurs – Infections Tropicales et Méditerranéennes (VITROME), Service de santé des armées (SSA), 13005 Marseille, France
³EA 3279: CEReSS – Health Service Research and Quality of Life Center, Service d’Evaluation Médicale, Aix Marseille Univ, Assistance Publique Hôpitaux de Marseille, 13005 Marseille, France
⁴Laboratoire D’Hématologie, Hôpital de La Timone, Assistance Publique Hôpitaux de Marseille, 13005 Marseille, France
⁵Service de Cardiologie, Centre Hospitalier Universitaire La Timone, Assistance Publique Hôpitaux de Marseille, Aix Marseille Univ, C2VN, 13005 Marseille, France
⁶Radiology Department, La Timone Hospital, Assistance Publique Des Hôpitaux de Marseille, Aix Marseille Univ, LIIE, CERIMED, 13005 Marseille, France
⁷Service de Pharmacie, Hôpital Timone, Laboratoire de Pharmacie Clinique, Aix Marseille Université AP-HM, 13005 Marseille, France

Download: PDF(2238KB) ( 2881 ) Full text ( 1401 )
Export: BibTeX | EndNote (RIS)

Abstract:
We evaluated the age-specific mortality of unselected adult outpatients infected with SARS-CoV-2 treated early in a dedicated COVID-19 day hospital and we assessed whether the use of hydroxychloroquine (HCQ) + azithromycin (AZ) was associated with improved survival in this cohort. A retrospective monocentric cohort study was conducted in the day hospital of our center from March to December 2020 in adults with PCR-proven infection who were treated as outpatients with a standardized protocol. The primary endpoint was 6-week mortality, and secondary endpoints were transfer to the intensive care unit and hospitalization rate. Among 10,429 patients (median age, 45 [IQR 32–57] years; 5597 [53.7%] women), 16 died (0.15%). The infection fatality rate was 0.06% among the 8315 patients treated with HCQ+AZ. No deaths occurred among the 8414 patients younger than 60 years. Older age and male sex were associated with a higher risk of death, ICU transfer, and hospitalization. Treatment with HCQ+AZ (0.17 [0.06–0.48]) was associated with a lower risk of death, independently of age, sex and epidemic period. Meta-analysis evidenced consistency with 4 previous outpatient studies (32,124 patients—Odds ratio 0.31 [0.20–0.47], I² = 0%). Early ambulatory treatment of COVID-19 with HCQ+AZ as a standard of care is associated with very low mortality, and HCQ+AZ improve COVID-19 survival compared to other regimens.

Key words: SARS-CoV-2 COVID-19 Hydroxychloroquine Azithromycin Ambulatory Outpatients Treatment

Submitted: 10 August 2021 Revised: 27 August 2021 Accepted: 30 August 2021 Published: 24 September 2021

^*Corresponding Author(s): Matthieu MILLION E-mail: matthieu.million@gmail.com

	Service
	E-mail this article
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

Matthieu MILLION, Jean-Christophe LAGIER, Hervé TISSOT-DUPONT, Isabelle RAVAUX, Catherine DHIVER, Christelle TOMEI, Nadim CASSIR, Léa DELORME, Sébastien CORTAREDONA, Sophie AMRANE, Camille AUBRY, Karim BENDAMARDJI, Cyril BERENGER, Barbara DOUDIER, Sophie EDOUARD, Marie HOCQUART, Morgane MAILHE, Coralie PORCHETO, Piseth SENG, Catherine TRIQUET, Stéphanie GENTILE, Elisabeth JOUVE, Audrey GIRAUD-GATINEAU, Herve CHAUDET, Laurence CAMOIN-JAU, Philippe COLSON, Philippe GAUTRET, Pierre-Edouard FOURNIER, Baptiste MAILLE, Jean-Claude DEHARO, Paul HABERT, Jean-Yves GAUBERT, Alexis JACQUIER, Stéphane HONORE, Katell GUILLON-LORVELLEC, Yolande OBADIA, Philippe PAROLA, Philippe BROUQUI, Didier RAOULT. Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients. Reviews in Cardiovascular Medicine, 2021, 22(3): 1063-1072.